WANBURY

BSE: 524212 29 Jun 2025

Healthcare

₹ 272.75

Wanbury Limited specializes in Pharmaceuticals within the Healthcare sector.

WANBURY

BSE: 524212 29 Jun 2025

Healthcare

₹ 272.75

Wanbury Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

18.1

Dividend Yield

0.0%

Debt to Equity

2.98

Stock P/E

29.8

Market Cap

909.0 Cr

WANBURY - Share Price & Details

Market Cap

₹909.0

High /Low

330.0 / 151.0

Stock P/E

29.8

Book Value

₹18.1

Dividend Yield

0.0

ROCE

34.9

ROE

₹70.0

Face Value

10.0

PEG Ratio

1.0

EVEBITDA

₹13.4

Debt

177

CMP / FCF

-108.0

Debt to equity

₹2.98

NP Ann

30.5

High price all time

330.0

Piotroski score

₹3.0

Graham Number

61.6

No. Eq. Shares

3.28

Net CF

₹0.66

Net profit

30.5

Price to book value

15.3

Interest Coverage

₹1.8

Low price all time

10.8

Industry PE

32.0

Reserves

₹26.5

Free Cash Flow

₹-22.5

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
LOOKS HEALTH SERVICES LIMITED	NA	NA	NA	NA	5.11	256.0
Triochem Products Ltd.,	NA	NA	NA	NA	0
WANBURY LTD.	1738.44	202.56	1719.99	5.98	909.0	29.8
KOPRAN LTD.	778.52	85.99	759.35	1.78	902	23.4
Bharat Parenterals Limited	NA	NA	NA	NA	786	29.7

Peer Comparison Chart

About WANBURY

Wanbury Limited, with Security Code 524212, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Multibagger Share: 20 रुपयांच्या 'या' शेअरनं 5 वर्षात 1450 टक्के रिटर्न , गुंतवणूकदार मालामाल

(15 Jun 2025)

शेअर बाजारात जे जोखीम घेतील त्यांना फायदा मिळतो, असं म्हटलं जातं. ज्यांनी जोखीम घेतली त्यांना फायदा झाला असं म्हटलं जातं. ज्या स्टॉकमधून अधिक परतावा मिळतो त्याला मल्टीबॅगर स्टॉक म्हटलं जातं.

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside

(13 Jun 2025)

Wanbury stock has skyrocketed 1475% from ₹19 in June 2020 to ₹299.35, making a ₹1 lakh investment worth over ₹15.75 lakh.

कोरोना काल से तेजी दिखा रहा 20 रुपये वाला यह शेयर, बारह महीने में 99.99% रिटर्न, 5 साल में 14 गुना हुआ पैसा

(13 Jun 2025)

Wanbury Ltd Share वैनबरी लिमिटेड (Wanbury Ltd Share) का शेयर मल्टीबैगर स्टॉक साबित हुआ है। इस फार्मा शेयर ने 5 साल में 1450% रिटर्न दिया है। वैनबरी लिमिटेड के शेयरों का दाम कोरोना काल...

From Rs 18 to Rs 300: Ventura initiates coverage on this multibagger, see up to 52% upside

(12 Jun 2025)

Domestic brokerage firm Ventura Securities has initiated coverage of Wanbury Ltd with a 'buy' recommendation, suggesting a 52% upside in the...

Has Wanbury declared dividend?

(07 Jun 2025)

Yes, Wanbury Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 29, 2010. However, the dividend yield is 0%,...

Subdued Growth No Barrier To Wanbury Limited (NSE:WANBURY) With Shares Advancing 26%

(31 May 2025)

Despite an already strong run, Wanbury Limited ( NSE:WANBURY ) shares have been powering on, with a gain of 26% in the...

Quarterly Table

Standalone Consolidated

Metrics	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	124.0	125.8	133.0	146.3	144.5	145.5	139.4	131.1	161.2	133.5
Expenses	118.4	119.3	118.8	132.9	127.1	124.4	121.2	120.1	141.2	119.5
Operating Profit	5.6	6.5	14.2	13.3	17.3	21.1	18.2	11.0	20.0	13.9
OPM %	4.51%	5.13%	10.65%	9.12%	12.01%	14.53%	13.03%	8.37%	12.41%	10.45%
Other Income	0.8	0.3	-2.7	0.6	0.8	0.7	0.9	0.9	1.6	0.8
Interest	3.9	6.6	7.5	5.8	7.7	8.3	7.5	7.6	10.1	10.2
Depreciation	3.2	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3
Profit before tax	-0.7	-3.0	1.5	5.0	7.2	10.3	8.3	1.0	8.2	1.3
Tax %	25.4%	7.6%	10.3%	-6.1%	2.4%	0.2%	-3.3%	0%	-1.8%	5.7%
Net Profit	-0.9	-3.3	1.0	4.7	7.4	10.3	8.1	1.0	8.0	1.2
EPS in Rs	-0.27	-1	0.8	1.43	2.25	3.14	2.37	0.31	2.44	0.7

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	125.8	133.0	146.3	144.5	145.5	139.4	131.1	161.2	133.5	172.0
Expenses	119.3	118.8	132.9	127.1	124.4	121.2	120.1	141.2	119.5	142.4
Operating Profit	6.5	14.2	13.3	17.3	21.1	18.2	11.0	20.0	13.9	29.6
OPM %	5.13%	10.65%	9.12%	12.01%	14.53%	13.03%	8.37%	12.41%	10.45%	17.22%
Other Income	0.3	-2.7	0.6	0.8	0.7	0.9	0.9	1.6	0.8	1.8
Interest	6.6	7.5	5.8	7.7	8.3	7.5	7.6	10.1	10.2	9.0
Depreciation	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4
Profit before tax	-3.0	1.5	5.0	7.2	10.3	8.3	1.0	8.2	1.3	19.1
Tax %	7.6%	10.3%	-6.1%	2.4%	0.2%	0.8%	0%	1.8%	-5.7%	-6.3%
Net Profit	-3.3	1.0	4.7	7.4	10.3	33.6	1.0	8.0	1.2	20.3
EPS in Rs	-1	0.8	1.43	2.25	3.13	12.45	0.31	2.34	0.7	5.98

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	5%
TTM:	4%

Compounded Profit Growth
10 Years:	25%
5 Years:	30%
3 Years:	78%
TTM:	2%

Stock Price CAGR
10 Years:	17%
5 Years:	74%
3 Years:	62%
1 Year:	95%

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	5%
TTM:	8%

Compounded Profit Growth
10 Years:	25%
5 Years:	30%
3 Years:	75%
TTM:	-8%

Stock Price CAGR
10 Years:	17%
5 Years:	74%
3 Years:	62%
1 Year:	95%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

WANBURY

WANBURY

WANBURY - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About WANBURY

Latest News

Multibagger Share: 20 रुपयांच्या 'या' शेअरनं 5 वर्षात 1450 टक्के रिटर्न , गुंतवणूकदार मालामाल

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside

कोरोना काल से तेजी दिखा रहा 20 रुपये वाला यह शेयर, बारह महीने में 99.99% रिटर्न, 5 साल में 14 गुना हुआ पैसा

From Rs 18 to Rs 300: Ventura initiates coverage on this multibagger, see up to 52% upside

Has Wanbury declared dividend?

Subdued Growth No Barrier To Wanbury Limited (NSE:WANBURY) With Shares Advancing 26%

Wanbury's (NSE:WANBURY) Anemic Earnings Might Be Worse Than You Think

Wanbury Secures GMP Certification from Brazil Health Agency; Shares Slump 4%

Wanbury receives GMP certification from Brazil health regulator for its facility in Raigad, Maharashtra

Wanbury Secures ANVISA GMP Certification for Maharashtra Facility

Wanbury's Patalganga facility receives GMP certification from ANVISA

Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr

Zee Learn Ltd leads gainers in 'B' group

Pharma stock skyrockets 19% after reporting 1,570% QoQ increase in net profit

Wanbury's Tanuku facility granted GMP certificate by ANVISA

Wanbury Standalone March 2025 Net Sales at Rs 172.00 crore, up 23.38% Y-o-Y

Wanbury standalone net profit rises 150.74% in the March 2025 quarter

Rajani Associates advises Wanbury Ltd on ₹200 crore NCD issuance

Wanbury Limited to implement the SAP S/4 HANA Private Cloud Platform

Wanbury to implement the SAP S/4 HANA private cloud platform

Expert Chemicals Affirms No New Share Encumbrances for FY 2025

India’s pharma sector spared from US tariff hikes as Wanbury plans investor visit

Wanbury Limited's (NSE:WANBURY) Shares Bounce 31% But Its Business Still Trails The Market

Wanbury to launch new iron supplement C-RED & API Ketamine

Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE

Wanbury Limited Announces Financial Results and Capital Raising Initiatives

Pharma firm Wanbury refinances debt, cuts interest costs significantly

Wanbury Limited Strengthens Board with New Director Appointments

Wanbury refinances $150 cr debt, cuts interest costs significantly

Wanbury Faces Financial Struggles Amid Declining Sales and High Debt Concerns

Wanbury edges higher post conclusion of NCD refinancing at lower rates

Wanbury reports 88% drop in Q3 FY25 PAT

Benign Growth For Wanbury Limited (NSE:WANBURY) Underpins Stock's 28% Plummet

Wanbury Board approves fundraising and stock options grant; stocks down by 1%

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility

Wanbury Limited's (NSE:WANBURY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Wanbury Experiences Revision in Its Stock Evaluation Amidst Strong Market Performance

We Believe Wanbury's (NSE:WANBURY) Earnings Are A Poor Guide For Its Profitability

Wanbury Standalone September 2024 Net Sales at Rs 161.19 crore, up 11.58% Y-o-Y

Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

Is Wanbury (NSE:WANBURY) Using Too Much Debt?

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

Akums Drugs & Pharmaceuticals promotes Jitendra Mishra as Senior Vice President

Wanbury Limited (NSE:WANBURY) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Wanbury Shares Hit 5% Upper Circuit on API Pipeline and Launches

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury Gets European CEP for Cough Relief Drug, Shares Flat

Wanbury receives Certificate of Suitability (CEP) for cough relief drug in Europe

Wanbury gets Certificate of Suitability for cough relief medicine in Europe

Wanbury Shares Surge 5% on Receiving Form 483 With Zero Observation

Wanbury Consolidated June 2024 Net Sales at Rs 131.11 crore, down 10.38% Y-o-Y

Wanbury bags safety awards for its API manufacturing site in Patalganga

Wanbury appoints Pradeep Patni as CEO of India Formulation Business

Wanbury Appoints Pradeep Patni as CEO of India Formulation Business

Wanbury ropes in Prakash Venkatraman as President of API business

Wanbury Appoints Prakash Venkatraman As President Of API Business

Wanbury appoints Prakash Venkatraman as President of API Business

Wanbury appoints Prakash Venkatraman as president of API business

Wanbury Appoints Prakash Venkatraman as President of API Business

Wanbury Limited (NSE:WANBURY) Might Not Be As Mispriced As It Looks

Top stocks giving multi-year breakouts

Expert Chemicals raises stake in Wanbury

ASM List – What to do in ASM list Stocks?

Wanbury shares rise 5% after clean US FDA report on Patalganga facility

Wanbury's Patalganga manufacturing facility clears U.S. FDA inspection with zero observations

Wanbury Shares Shot-Up 5% as USFDA Issues 0 Observations

Wanbury surges 5% after USFDA issues Zero observations for Patalganga site

Wanbury announces successful completion of US FDA inspection at Patalganga site, Maharashtra

Wanbury gains 5% on conclusion of USFDA inspection at Maharashtra unit with zero observation

Wanbury Q4 Results Live : profit rise by 3211.99% YOY | Company Business News

Wanbury Q4 Results Live : profit rise by 3211.99% YOY